Around $14bil USD. Really. Doesnt sound too far fetched to me considering what could potentially be on the table for big pharma to purchase. All you need to do is look at the potential use cases for Zantrene from Masons or JDPs tables and think its a steal at $14bil.
Speculative M&A Transaction Analysis, page-784
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $273.5M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.61 | $159.4K | 98.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5684 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |